AMGNAmgen
$439.33+1.88%Real quote · delayedBiopharma🏛️ Company factsSEC filings + FINRA official data
Annual revenue $36.8B · latest quarter up 9.5% YoY · profitable (FY net income $7.7B) · short activity within its normal range.
FY revenue
$36.8B
2025-12
Latest Q YoY
+9.5%
Gross margin
18.6%
FY net income
$7.7B
Diluted EPS
$14.33
Short volume
51%
20d avg 55.8% · normal
🐋 5%+ ownership filings (last 180d)
The parties below hold over 5% of this company and disclosed it to the SEC (mandatory in US markets). "Activist" filers state an intent to influence the company; "Passive" are pure investment positions.
- 2026-05-14passive (13G)Capital World Investors
- 2026-04-29passive (13G)VANGUARD CAPITAL MANAGEMENT LLC
- 2026-03-26passive (13G)VANGUARD GROUP INC
🎯 Market expectations
Expectation reliability High · 76/100Nasdaq analyst consensus · the pre-news baseline
- Jun 2026$6.29 vs $5.60+12.32%
- Mar 2026$5.15 vs $4.73+8.88%
- Dec 2025$5.29 vs $4.76+11.13%
- Sep 2025$5.64 vs $5.00+12.8%
This company habitually beats by +11.3% — the next report has to clear that bar to count as good news. Analysts cut estimates 4× in 4 weeks.
Analyst estimates, not our forecast · not investment advice
🕰️ Price × news · engine report card
Drag to pan, scroll to zoom · dot = engine's call · color = outcome, arrow = direction
📜 Call history (newest first
12 engine calls on this stock — each with direction, magnitude and its verified outcome · sign up to view
Sign up · free 7-day trial →Impact chains · crowding · conviction engine · insider signals — free 7-day trial on signup.
Sign up · free 7-day trial →